Current diagnostics are not good enough for rapid, accurate and early detection of diseases. For current and future pandemic preparedness, the world is in need of revolutionary diagnostics strategies that can be rapidly developed and deployed to accurately test for any emerging pathogen.

InnoTech Precision Medicine
At A Glance

Early detection of disease saves lives. Current diagnostics fall short in rapid and accurate detection of diseases at an early stage when life-saving treatments are viable. InnoTech’s novel solution leverages proprietary synthetic biosensor technology, outperforms conventional diagnostics with improved speed to make diagnostics for new pathogens that provide accuracy, scalability and cost effectiveness. Our licensing partnership with MIT ensures our exclusive rights of use.

InnoTech’s platform will first target the global COVID-19 diagnostics market, $84.4B in 2021 and $195.1B by 2028, with ample opportunity to expand into the general molecular diagnostics and emerging infectious diseases industries.

For a fast go to market strategy based on the emergency status of COVID pandemic, our first product, Recognize™-COVID, will provide rapid testing for detection of SARS-CoV-2  at earlier stages of the disease and with higher accuracy than the current rapid tests.  An accurate, rapid and portable test for COVID is urgently needed to combat the current pandemic.

Conventional Molecular
Diagnostics Fall Short

Conventional rapid diagnostics have several inherent shortcomings that provide inaccurate or delayed test results, leading to poor treatment outcomes.

These issues are particularly apparent in SARS-CoV-2 diagnostics, where early diagnosis is crucial for preventing severe disease, saving lives and containing virus outbreaks.

Other conventional molecular diagnostics, PCR tests, are complex to administer, slow to deliver results, and highly expensive.

Novel Synthetic
Biosensor Technology

InnoTech’s novel synthetic biosensors provide increased diagnostic accuracy while being easy to administer, portable, inexpensive and delivering results within minutes.

Whereas conventional rapid diagnostics rely on natural antibodies, which take a long time to develop for a new disease, are prone to inaccuracy and have limited use, our sensors are based on synthetic technology that can be multiplexed effectively to sense multiple classes of biomarkers in one test, significantly enhancing their accuracy.

InnoTech’s biosensor technology is also more cost-effective as the synthetic nature of our sensors allows for rapid, scalable manufacturing. Due to their enhanced stability, our technology is easily-deployable for global distribution.

Our solution can be incorporated into the existing clinical workflow as well. Using easily collectable oral specimen and multiple biosensors per test, our technology delivers highly-accurate results in minutes with no specialized lab required.

How It Works

Recent Traction & Accomplishments

InnoTech’s Executive Team

Roya Khosravi-Far, Ph.D.; PLD CEO and CTO | Dr. Khosravi-Far is a Microbiologist, Molecular and Cellular Biologist, Immunologist and entrepreneur. She brings over 30 years of experience in precision and translational medicine in academia, including Professor at Harvard Medical School, and the biotech industry at both scientific and business leadership levels. 

Richard DeVito, MS, Product Manager | Mr. DeVito is a physicist and has over 30 years of experience in micro and nanofabrication and device engineering and production at small and large companies including P&G, Draper, MKS, Corning and Raytheon.

Reza Mollaaghababba, Ph.D, J.D. | Dr. Mollaaghababba is a physicist and patent attorney and has over 30 years of experience in device engineering and IP strategy.

Joe St. Germain, Outside CFO/Controller | Mr. St. Germain has over 20 years of executive-level experience in financial management to fuel strategic growth.